WO1998054333A3 - Mammalian caax processing enzymes - Google Patents

Mammalian caax processing enzymes Download PDF

Info

Publication number
WO1998054333A3
WO1998054333A3 PCT/US1998/011415 US9811415W WO9854333A3 WO 1998054333 A3 WO1998054333 A3 WO 1998054333A3 US 9811415 W US9811415 W US 9811415W WO 9854333 A3 WO9854333 A3 WO 9854333A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammalian
caax
sequences
protein
dna
Prior art date
Application number
PCT/US1998/011415
Other languages
French (fr)
Other versions
WO1998054333A2 (en
Inventor
Matthew N Ashby
Dago G Dimster-Denk
John W Philips
Original Assignee
Acacia Biosciences Inc
Matthew N Ashby
Dimster Denk Dago G
John W Philips
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acacia Biosciences Inc, Matthew N Ashby, Dimster Denk Dago G, John W Philips filed Critical Acacia Biosciences Inc
Priority to AU77216/98A priority Critical patent/AU7721698A/en
Publication of WO1998054333A2 publication Critical patent/WO1998054333A2/en
Publication of WO1998054333A3 publication Critical patent/WO1998054333A3/en
Priority to US09/454,889 priority patent/US6518035B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides mammalian DNA sequences that display a high degree of sequence identity to their Saccharomyces cerevisae counterparts, RCE1 and AFC1. Specifically, complementary DNA (cDNA) sequences of the human and mouse RCE functional homologs are provide. Human cDNA sequences encoding proteins having a high degree of amino acid sequence identity to the yeast Afc1p protein are also provided. This invention is also directed to recombinant DNA molecules comprising the mammalian DNA sequences, DNA molecules and antisense RNA molecules which hybridize under stringent hybridization conditions to those DNA sequences, hosts transformed with their recombinant DNA molecules and protein expression products produced by culturing the transformed hosts. Antibodies directed against the protein expression products are also provided. Also provided are assays to identify inhibitors of one or more mammalian CAAX processing enzymes and kits for making the above products and performing the above assays. Finally, this invention provides pharmaceutical compositions comprising an inhibitor of a mammalian CAAX processing enzyme, and methods for treating a CAAX-protein mediated disease or disorder in a patient by administering such a pharmaceutical composition..
PCT/US1998/011415 1997-06-02 1998-06-02 Mammalian caax processing enzymes WO1998054333A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU77216/98A AU7721698A (en) 1997-06-02 1998-06-02 Mammalian caax processing enzymes
US09/454,889 US6518035B1 (en) 1998-06-02 1999-12-03 Targeted methods of drug screening using co-culture methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4736997P 1997-06-02 1997-06-02
US60/047,369 1997-06-02
US5238997P 1997-07-14 1997-07-14
US60/052,389 1997-07-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US21312098A Continuation 1998-06-02 1998-12-15

Publications (2)

Publication Number Publication Date
WO1998054333A2 WO1998054333A2 (en) 1998-12-03
WO1998054333A3 true WO1998054333A3 (en) 1999-04-08

Family

ID=26724942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/011415 WO1998054333A2 (en) 1997-06-02 1998-06-02 Mammalian caax processing enzymes

Country Status (1)

Country Link
WO (1) WO1998054333A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060277A (en) * 1997-06-24 2000-05-09 Smithkline Beecham Corporation Human AFC1
CA2234418A1 (en) * 1997-06-24 1998-12-24 Smithkline Beecham Corporation Human afc1
ES2149672B1 (en) * 1998-01-08 2001-05-16 Univ Oviedo HUMAN GENE SEQUENCE APPROVES THE AFC1 GENE OF LEAVES INVOLVED IN THE PROTEOLITIC PROCESSING OF PRENILED PROTEINS.
US6417332B1 (en) * 1998-02-12 2002-07-09 Smithkline Beecham Corporation Human RCE1
EP1078076A2 (en) * 1998-05-22 2001-02-28 Onyx Pharmaceuticals, Inc. Novel nucleic acids and polypeptides related to a farnesyl-directed endopeptidase
US6518035B1 (en) 1998-06-02 2003-02-11 Rosetta Inpharmatics, Inc. Targeted methods of drug screening using co-culture methods
US6261793B1 (en) * 1999-03-04 2001-07-17 Schering Corporation RAS converting endoprotease (RCE) and methods
US6730786B2 (en) * 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679716A1 (en) * 1993-11-12 1995-11-02 Kenichi Matsubara Gene signature
WO1998005786A2 (en) * 1996-08-07 1998-02-12 The Regents Of The University Of California Afc1 and rce1:isoprenylated caax processing enzymes
EP0887416A2 (en) * 1997-06-24 1998-12-30 Smithkline Beecham Corporation Human AFC1
EP0887415A2 (en) * 1997-06-24 1998-12-30 Smithkline Beecham Corporation Human RCE1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679716A1 (en) * 1993-11-12 1995-11-02 Kenichi Matsubara Gene signature
WO1998005786A2 (en) * 1996-08-07 1998-02-12 The Regents Of The University Of California Afc1 and rce1:isoprenylated caax processing enzymes
EP0887416A2 (en) * 1997-06-24 1998-12-30 Smithkline Beecham Corporation Human AFC1
EP0887415A2 (en) * 1997-06-24 1998-12-30 Smithkline Beecham Corporation Human RCE1

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AKOPYAN T.N. ET AL.: "Proteolytic processing of farnesylated peptides: assay and partial purification from pig brain membranes of an endopeptidase which has the characteristics of E.C. 3.4.24.15", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 198, no. 2, 28 January 1994 (1994-01-28), pages 787 - 794, XP002049582 *
BOYARTCHUK V.L. ET AL.: "Modulation of Ras and a-factor function by carboxyl-terminal proteolysis", SCIENCE, vol. 275, 21 March 1997 (1997-03-21), pages 1796 - 1800, XP002049583 *
CHEN Y. ET AL.: "Solubilization, partial purification, and affinity labeling of the membrane-bound isoprenylated protein endoprotease", BIOCHEMISTRY, vol. 35, 12 March 1996 (1996-03-12), pages 3227 - 3237, XP000199958 *
Database EMBL Emest12, Entry HSAA19855 Accession number AA210930 2 February 1997 96% identity with Seq.ID:37 nt.216-590 *
Database EMBL Emest13, Entry HSW4115 Accession number W96411 18 July 1996 98% identity with Seq.ID:1 nt.488-841 88% identity with Seq.ID:3 nt.481-830 reverse orientation *
Database EMBL Emest15, Entry MM3448 Accession number W14344 30 April 1996 87% identity with Seq.ID:1 nt.617-990 100% identity with Seq.ID:3 nt.610-983 *
Database EMBL Emest16, Entry MMAA21859 Accession number AA021859 29 November 1996 89% identity with Seq.ID:1 nt.7-664 98% identity with Seq.ID:3 nt.3-672 *
Database EMBL Emest16, Entry MMAA68614 Accession number AA168614 22 December 1996 90% identity with Seq.ID:1 nt.390-839 100% identity with Seq.ID:3 nt.383-832 *
Database EMBL Emest18, Entry HSZZ64182 Accession number AA359058 18 April 1997 100% identity with Seq.ID:37 nt.1-306 *
Database EMBL Emest8, Entry HS1228356 Accession number AA428315 25 May 1997 100% identity with Seq.ID:1 nt.130-529 90% identity with Seq.ID:3 nt.123-522 *
Database EMBL Emest8, Entry HS181310 Accession number N76181 5 April 1996 100% identity with Seq.ID:37 nt.430-721 *
NISHII W. ET AL.: "Partial purification and characterization of a CAAX-motif-specific protease from bovine brain using a novel fluorometric assay", JOURNAL OF BIOCHEMISTRY, vol. 122, 1997, pages 402 - 408, XP000199959 *

Also Published As

Publication number Publication date
WO1998054333A2 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
Doersen et al. Characterization of an RNase P activity from HeLa cell mitochondria. Comparison with the cytosol RNase P activity.
Marie et al. The 69-kDa 2-5A synthetase is composed of two homologous and adjacent functional domains.
Johnston et al. Nucleotide sequence of the luxB gene of Vibrio harveyi and the complete amino acid sequence of the beta subunit of bacterial luciferase.
Wong et al. DNA primase of human mitochondria is associated with structural RNA that is essential for enzymatic activity
Clayton et al. The procyclic acidic repetitive proteins of Trypanosoma brucei: purification and post-translational modification
Robbins et al. Structural and immunological similarities between simian sarcoma virus gene product (s) and human platelet-derived growth factor
Schnapp et al. Function of the growth-regulated transcription initiation factor TIF-IA in initiation complex formation at the murine ribosomal gene promoter
Worland et al. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae
O'Farrell et al. Structure and processing of yeast precursor tRNAs containing intervening sequences
Bernardi 11 spleen acid deoxyribonuclease
Tsai et al. Mouse mammary tumor virus gene expression is suppressed by oligomeric ellagitannins, novel inhibitors of poly (ADP-ribose) glycohydrolase.
Aiello et al. Chemical and biological characterization of spirulina protein hydrolysates: Focus on ACE and DPP-IV activities modulation
Teng et al. Evolution of intestinal apolipoprotein B mRNA editing. Chicken apolipoprotein B mRNA is not edited, but chicken enterocytes contain in vitro editing enhancement factor (s).
ATE318896T1 (en) RECOMBINANT RNA REPLICASE OF HEPATITIS C VIRUS
HUP0004611A2 (en) April- a novel protein with growth effects
DE69840387D1 (en) NIK PROTEIN, NUCLEIC ACID AND METHOD
Eppstein et al. Mechanism of interferon action Properties of an interferon-mediated ribonucleolytic activity from mouse L9z9 cells
WO1998054333A3 (en) Mammalian caax processing enzymes
Thorpe et al. Extended cleavage specificity of the mast cell chymase from the crab-eating macaque (Macaca fascicularis): an interesting animal model for the analysis of the function of the human mast cell chymase
Schmitz et al. Hyaluronan oligosaccharide treatment of chondrocytes stimulates expression of both HAS-2 and MMP-3, but by different signaling pathways
Gonen et al. Protein synthesis elongation factor EF-1α is an isopeptidase essential for ubiquitin-dependent degradation of certain proteolytic substrates
Huang et al. Role of Calf RTH-1 Nuclease in Removal of 5 ‘-Ribonucleotides during Okazaki Fragment Processing
Pereira et al. Carboxypeptidases A1 and A2 from the perfusate of rat mesenteric arterial bed differentially process angiotensin peptides
WO2004005475A3 (en) Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
Yamada et al. Characterization of the platelet-activating factor acetylhydrolase from human plasma by heterologous expression in Xenopus laevis oocytes.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09213120

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999501041

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA